Inhibitory effects of tocilizumab on serum oxidative stress in patients with rheumatoid arthritis -comaparison with other biologic agents-

Inhibitory effects of tocilizumab on serum oxidative stress in patients with rheumatoid arthritis -comaparison with other biologic agents- - Inhibitory effects of tocilizumab on serum oxidative stress in patients with RA

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018659

Enrollment

Registered

2015-08-13

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. RA patients on moderate or high disease activity 2. Biologics-naive patients

Exclusion criteria

Exclusion criteria: 1. RA patients on remission or low disease activity 2. Patients who have recieved biologic agents 3. Patients who have suffered from severe infection disease or have high risk factors

Design outcomes

Primary

Measure	Time frame
Serum levels of ROM, CRP, MMP3, and DAS28 twenty-four weeks after tocilizumab or other biologics administration	—

Countries

Japan

Contacts

Public ContactArata Nakajima

Toho University Sakura Medical Center Orthopedics

arata.nakajima@med.toho-u.ac.jp043-462-8811

Outcome results